Introduction
============

Multiple myeloma (MM), also known as plasma cell myeloma, is an incurable cancer formed by malignant plasma cells.[@b1-ott-10-1327] As the second most common cancer of the blood next only to non-Hodgkin's lymphoma, each year, over 20,000 new cases are diagnosed in the USA according to epidemiologic studies from the American Cancer Society.[@b2-ott-10-1327] Over the last 40 years, therapy with melphalan plus prednisone has been recognized as the standard of care for patients with newly diagnosed MM.[@b3-ott-10-1327] However, older patients and patients with clinically significant coexisting illnesses may not be eligible for high-dose therapy and usually do not tolerate this treatment. For these patients, the proteasome inhibitors (bortezomib and carfilzomib) are active in relapsed or refractory myeloma, which were approved by the Food and Drug Administration for treatment of relapsed/refractory MM in 2003 and 2012, respectively.[@b4-ott-10-1327] In preclinical studies, bortezomib and carfilzomib sensitized melphalan-sensitive and melphalan-resistant myeloma cell lines to melphalan by breaking down enzyme complexes and downregulated cellular responses to genotoxic stress.[@b5-ott-10-1327] However, recent studies revealed that relapse of myeloma developed due to acquisition of resistance to proteasome inhibitors, owing to the mutations of proteasome complex,[@b6-ott-10-1327] upregulation of transporter channels or cytochrome components[@b7-ott-10-1327] and the induction of alternative compensatory pathways.[@b8-ott-10-1327] Although several aspects of the mechanisms associated with acquisition of resistance to proteasome inhibitors have been studied, a systems biological perspective in terms of proteasome inhibitors resistance for MM has not been fully elucidated.

In recent years, with the rapid development of precision medicine, it is possible to analyze high-throughput screening dataset to better understand pathogenesis in terms of disease progression and drug therapeutics.[@b9-ott-10-1327]--[@b11-ott-10-1327] To better address this merit, herein, we identified a microarray gene expression profile originating from the carfilzomib-resistant KMS-11 versus parental human myeloma cell line to establish a comprehensive genetic interaction network in order to reveal the molecular mechanisms in carfilzomib resistance in MM, which may provide molecular information or targets for MM clinical interventions in terms of acquisition of resistance to proteasome inhibitors.

Materials and methods
=====================

Microarray dataset search strategy
----------------------------------

Microarray dataset was downloaded from Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>) with the accession number GSE69078. In this study, Riz et al treated KMS-11 MM cell line with increasing concentrations of carfilzomib over a period of 18 weeks to establish the carfilzomib-resistant MM cell line.[@b8-ott-10-1327] Total RNA was extracted from the KMS-11 cell line with or without carfilzomib treatment, and messenger RNA array was performed based on Affymetrix Human Genome U133 Plus 2.0 platform.

Differently expressed genes identification
------------------------------------------

Comparison of the gene expression profiles of carfilzomib-resistant derivatives versus parental human KMS-11 MM cell line was normalized using log~2~ transformation after normalization. Significance Analysis of Microarrays (SAM, <http://statweb.stanford.edu/~tibs/SAM/>), a statistical technique for finding significant genes in a set of microarray experiments, was applied according to a previous publication.[@b12-ott-10-1327]

Genetic interaction network construction
----------------------------------------

To better understand how these significant genes identified by SAM interacted with each other, genetic interaction network was expanded using String JAVA consortium (<http://string-db.org/>). String, a website-based biomolecular interaction network database, has an application programming interface which enables the user to get the data without using the graphical user interface of the web page.

To better understand the potential drug-resistant mechanisms in MM, Gene Ontology consortium (GO; <http://www.geneontology.org/>) and Kyoto Encyclopedia of Genes and Genomes (<http://www.genome.jp/kegg/>) functional enrichment were also applied through Database for Annotation, Visualization and Integrated Discovery[@b13-ott-10-1327] (<https://david.ncifcrf.gov/>) plug-in in String database.

Statistical analysis
--------------------

For differently expressed genes identification, gene expression was considered to be significant if the threshold of false discovery rate was ≤5% and fold change was ≥2. For GO and Kyoto Encyclopedia of Genes and Genomes enrichment analysis, biological process, molecular function and signaling pathways were identified as different if the *P*-value was ≤5%.

Results
=======

Sixty-three genes were found to be significantly expressed in carfilzomib-resistant KMS-11 cells
------------------------------------------------------------------------------------------------

To better understand which regulators contribute to carfilzomib resistance in KMS-11 cells, differently expressed genes were screened out using SAM plug-in in Excel frame. As shown in [Figure 1](#f1-ott-10-1327){ref-type="fig"}, after performing SAM, 63 genes were found to be differently expressed in carfilzomib-resistant KMS-11 cell line compared to its parental one, with a false discovery rate ≤5% and a fold change ≥2. [Figure 2](#f2-ott-10-1327){ref-type="fig"} reveals the heatmap representation of these 63 genes, which indicates that 27 genes were upregulated and 36 genes decreased dramatically. The detailed information of these genes could be found in [Table 1](#t1-ott-10-1327){ref-type="table"}.

Carfilzomib-resistant genetic interaction network
-------------------------------------------------

To address the merit of systems biology and deepen our understanding toward how these genes regulated carfilzomib resistance in MM in a system perspective, all these significant genes were submitted to String bioinformatics platform future analysis. As shown in [Figure 3](#f3-ott-10-1327){ref-type="fig"}, the interaction network involved in carfilzomib resistance consists of 100 nodes (genes) and 249 edges (molecular interaction), with the average node degree (the number of edges connected to the node) being 4.98. Besides, network analysis also indicated that the clustering coefficient and protein--protein interaction enrichment *P*-value were 0.788 and 5.41e^−12^, respectively, which means the network has a reliable robustness.

GO analysis
-----------

To assess the protein--protein interaction network involved in carfilzomib resistance in the context of GO, all the nodes were submitted to Database for Annotation, Visualization and Integrated Discovery bioinformatics platform for further functional annotation. As shown in [Table 2](#t2-ott-10-1327){ref-type="table"}, molecular function analysis indicated that most of these genes regulated protein or enzyme binding and activities. Besides, we also evaluated the biological processes involved in this carfilzomib-resistant network ([Table 3](#t3-ott-10-1327){ref-type="table"}). [Table 3](#t3-ott-10-1327){ref-type="table"} summarizes all the potential biological processes for carfilzomib resistance. Among them, immune response, mitopahgy/macroautophagy and cellular stress ranked as top candidates.

Pathway enrichment analysis
---------------------------

To assess the relationship between the significantly expressed genes and carfilzomib resistance, we also evaluated the signaling pathways involved in this pathogenesis ([Table 4](#t4-ott-10-1327){ref-type="table"}). Notably, cytokine--cytokine receptor interaction, autophagy, ErbB signaling pathway, microRNAs in cancer and fatty acid metabolism pathways seem to confer carfilzomib resistance in human KMS-11 MM cell line.

Discussion
==========

Combined with bioinformatics, high-throughput screening has become a convenient assay for drug-resistance or off-target identification.[@b14-ott-10-1327],[@b15-ott-10-1327] As early as 2003, a glass-based microarray suitable for detecting multiple tetracycline (*tet*) resistance genes was developed and applied.[@b16-ott-10-1327] Then, Hongisto et al developed a high-throughput three-dimensional (3D) screening method that revealed drug sensitivities between the culture models of JIMT1 breast cancer cells. Compared with the traditional method for studying cancer in vitro, the anchorage-independent three-dimensional models allowed cells to grow in two dimensions and resulted in screening out 102 compounds with multiple concentrations and biological replicates for their effects on breast cancer cell proliferation.[@b17-ott-10-1327] Using a similar method, in the present study, we also established a genetic interaction network using the publicly available microarray dataset and the functional protein interaction platform -- String. Our results revealed that cytokine--cytokine receptor interaction, autophagy, ErbB signaling pathway, microRNAs (miRNAs) in cancer and fatty acid metabolism pathways were highly associated with carfilzomib resistance in MM.

A previous study indicated that autophagy contributed to carfilzomib resistance in MM by KLF4-SQSTM1/p62, which proved our bioinformatics prediction between carfilzomib resistance and autophagy.[@b8-ott-10-1327] In this study, Riz et al identified high levels of *KLF4* expression often occurring in MM patients carrying the t(4;14) translocation, and acquisition of carfilzomib resistance in both t(4;14)-positive MM cell line models was associated with reduced cell proliferation, decreased plasma cell maturation and activation of prosurvival autophagy by regulation of *KLF4* expression.[@b8-ott-10-1327] Meanwhile, basing on the proteostasis network analysis by Acosta-Alvear et al,[@b18-ott-10-1327] inhibition of proteasome resulted in the compensatory mechanisms through inhibition of translation and induction of autophagy, which also confirmed our prediction regarding the role of autophagy in the acquisition of resistance to carfilzomib in MM.[@b18-ott-10-1327]

miRNAs, a group of noncoding RNA molecules composed of 19--25 nucleotides, can posttranscriptionally regulate target gene expression, which results in cell development, differentiation, apoptosis and proliferation.[@b19-ott-10-1327],[@b20-ott-10-1327] Besides, miRNAs are also involved in the development of drug resistance by miRNA dysregulation.[@b21-ott-10-1327] By far, several labs have already focused on exploring the role of miRNAs in drug resistance using microarrays. They discovered that the epigenetic modulations of miRNAs contributed to cancer drug resistance.[@b22-ott-10-1327] As to carfilzomib resistance, miRNA also plays a major role in regulating the fundamental cellular processes that control MM resistance to proteasome inhibitors.[@b23-ott-10-1327] Malek et al identified that the expression of miR29 family and Let-7A1 increased in response to bortezomib, carfilzomib and ixazomib. However, Let-7A2, Let-7D, Let-7E and Let-7F2 were downregulated in bortezomib-, carfilzomib-and ixazomib-resistant cells, compared to drug-sensitive parental cells. According to our bioinformatics analysis, *MTOR*, *EGFR*, *ERBB2*, *PDGFA*, *PDGFRA* and *PDGFRB* were involved in the subnetwork of miRNAs in cancer pathways. Since mammalian target of rapamycin (mTOR) inhibition can also induce autophagy,[@b24-ott-10-1327],[@b25-ott-10-1327] previous results also support the protective role of autophagy during proteasome inhibition, indicating that mTOR inhibition may desensitize carfilzomib both through inhibition of translation and induction of autophagy by regulation by miRNAs.[@b18-ott-10-1327]

As to the ErbB signaling pathway, the relation between drug resistance and ErbB pathway has already been predicted by Azad et al.[@b26-ott-10-1327] Using the Bayesian modeling framework, potential cross-talks between epidermal growth factor receptor (EGFR)/ErbB signaling and six other signaling pathways (Notch, Wnt, G protein coupled receptor \[GPCR\], hedgehog, insulin receptor/insulin-like growth factor 1 receptor \[IGF1R\] and transforming growth factor-beta \[TGF-b\] receptor signaling) contributed to drug resistance in breast cancer cell lines. However, limited information regarding carfilzomib resistance in MM is available.

Besides the signaling pathways mentioned above, we also discovered many pathways like valine, leucine and isoleucine degradation,[@b27-ott-10-1327] fatty acid metabolism, fatty acid degradation,[@b28-ott-10-1327] cysteine and methionine metabolism,[@b29-ott-10-1327] and terpenoid backbone biosynthesis, which are also involved in carfilzomib resistance in MM. However, detailed information regarding the association between these pathways and carfil-zomib resistance is not available. Notably, all these pathways seem to participate in cancer energy/nutrition metabolism. Whether there are any cross-talks between cancer metabolism and MM resistance is still unknown.

Conclusion
==========

In conclusion, using the integrated microarray gene expression profile and genetic interaction network, we explored the molecular mechanisms underlying carfilzomib resistance in MM cell line and highlighted some potential signaling pathways such as cytokine--cytokine receptor interaction, autophagy, ErbB signaling pathway, miRNAs in cancer and fatty acid metabolism pathways which may be involved in this process.
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![SAM plot result output of the gene expression profiling of the microarray dataset from GSE69078.\
**Note:** In this plot, red and green dots represent the gene sets that were up- and downregulated, respectively.\
**Abbreviation:** SAM, Significance Analysis of Microarray.](ott-10-1327Fig1){#f1-ott-10-1327}

![Heatmap visualization of the differently expressed genes identified by SAM in carfilzomib-resistant KMS-11 (GSM1692587, GSM1692588 and GSM1692589) versus parental human myeloma cell line (GSM1692593, GSM1692594 and GSM1692595).\
**Note:** In this picture, red represents upregulated genes, while green represents downregulated genes.\
**Abbreviation:** SAM, Significance Analysis of Microarray.](ott-10-1327Fig2){#f2-ott-10-1327}

![Genetic interaction network associated with carfilzomib resistance in multiple myeloma based on String platform. In this picture, each circle represents a gene (node) and each connection represents a direct or indirect connection (edge).\
**Note:** Line color indicates the type of interaction evidence and line thickness indicates the strength of data support.](ott-10-1327Fig3){#f3-ott-10-1327}

###### 

Significant genes identified by SAM in carfilzomib-resistant KMS-11 versus parental human myeloma cell line

  Gene ID        Gene name        Fold change   Gene regulation
  -------------- ---------------- ------------- -----------------
  202201_at      *BLVRB*          3.652113      Up
  219332_at      *MICALL2*        2.988681      Up
  208792_s\_at   *CLU*            2.831521      Up
  208791_at      *CLU*            2.87382       Up
  205943_at      *TDO2*           2.881487      Up
  235343_at      *VASH2*          2.793228      Up
  207469_s\_at   *PIR*            2.619397      Up
  205081_at      *CRIP1*          2.318266      Up
  244407_at      *CYP39A1*        2.900208      Up
  206140_at      *LHX2*           2.505247      Up
  205348_s\_at   *DYNC1I1*        2.19834       Up
  211458_s\_at   *GABARAPL1*      2.346701      Up
  223464_at      *OSBPL5*         2.171483      Up
  206435_at      *B4GALNT1*       2.188087      Up
  226884_at      *LRRN1*          2.112008      Up
  227307_at      *TSPAN18*        2.121718      Up
  219740_at      *VASH2*          2.261368      Up
  223633_s\_at   *BC005081*       2.245276      Up
  208869_s\_at   *GABARAPL1*      2.316713      Up
  203729_at      *EMP3*           2.063944      Up
  217728_at      *S100A6*         2.149586      Up
  232549_at      *RBM11*          2.141973      Up
  219489_s\_at   *NXN*            2.168232      Up
  222742_s\_at   *IFT22*          2.030835      Up
  214453_s\_at   *IFI44*          2.126185      Up
  223434_at      *GBP3*           2.010582      Up
  220432_s\_at   *CYP39A1*        2.042243      Up
  202983_at      *HLTF*           0.24513       Down
  204273_at      *EDNRB*          0.261948      Down
  228167_at      *KLHL6*          0.301736      Down
  213478_at      *KAZN*           0.367101      Down
  231202_at      *ALDH1L2*        0.318751      Down
  209723_at      *SERPINB9*       0.293765      Down
  204271_s\_at   *EDNRB*          0.359747      Down
  206701_x\_at   *EDNRB*          0.320717      Down
  205549_at      *PCP4*           0.398058      Down
  210644_s\_at   *LAIR1*          0.395248      Down
  47069_at       *PRR5*           0.447339      Down
  229830_at      *Unknown*        0.35393       Down
  205402_x\_at   *PRSS2*          0.44509       Down
  215071_s\_at   *HIST1H2AC*      0.455068      Down
  219259_at      *SEMA4A*         0.412331      Down
  213725_x\_at   *XYLT1*          0.444801      Down
  205016_at      *TGFA*           0.447057      Down
  219168_s\_at   *PRR5*           0.444994      Down
  206691_s\_at   *PDIA2*          0.466426      Down
  205822_s\_at   *HMGCS1*         0.411619      Down
  219255_x\_at   *IL17RB*         0.456308      Down
  205506_at      *VIL1*           0.472652      Down
  212816_s\_at   *CBS*            0.459518      Down
  218280_x\_at   *HIST2H2AA3*     0.499175      Down
  236451_at      *LOC100996579*   0.431235      Down
  225502_at      *DOCK8*          0.456397      Down
  220565_at      *CCR10*          0.470778      Down
  228821_at      *ST6GAL2*        0.394775      Down
  214455_at      *HIST1H2BC*      0.487997      Down
  205463_s\_at   *PDGFA*          0.469407      Down
  205898_at      *CX3CR1*         0.433747      Down
  209598_at      *PNMA2*          0.454474      Down
  216470_x\_at   *PRSS2*          0.46771       Down
  224156_x\_at   *IL17RB*         0.498466      Down
  208962_s\_at   *FADS1*          0.484027      Down
  225846_at      *ESRP1*          0.482879      Down

**Abbreviation:** SAM, Significant Analysis of Microarray.

###### 

Molecular function analysis of the genetic interaction network associated with carfilzomib resistance in KMS-11 cell line in terms of GO

  GO ID        Molecular function                                           Observed gene count   FDR
  ------------ ------------------------------------------------------------ --------------------- ----------
  GO.0003988   Acetyl-CoA C-acyltransferase activity                        5                     6.20E-08
  GO.0005515   Protein binding                                              42                    0.00197
  GO.0046983   Protein dimerization activity                                14                    0.00466
  GO.0042802   Identical protein binding                                    16                    0.0063
  GO.0005102   Receptor binding                                             17                    0.0073
  GO.0048407   Platelet-derived growth factor binding                       3                     0.0107
  GO.0005161   Platelet-derived growth factor receptor binding              3                     0.0124
  GO.0003774   Motor activity                                               6                     0.0164
  GO.0042803   Protein homodimerization activity                            11                    0.0202
  GO.0003985   Acetyl-CoA C-acetyltransferase activity                      2                     0.0243
  GO.0005017   Platelet-derived growth factor-activated receptor activity   2                     0.0243
  GO.0003824   Catalytic activity                                           41                    0.0257
  GO.0005125   Cytokine activity                                            6                     0.0257
  GO.0016740   Transferase activity                                         22                    0.0264
  GO.0019899   Enzyme binding                                               17                    0.0298
  GO.0038085   Vascular endothelial growth factor binding                   2                     0.0322
  GO.0004714   Transmembrane receptor protein tyrosine kinase activity      4                     0.049

**Abbreviations:** FDR, false discovery rate; GO, Gene Ontology.

###### 

Biological process analysis of the genetic interaction network associated with carfilzomib resistance in KMS-11 cell line in terms of GO

  GO ID        Biological process                                   Observed gene count   FDR
  ------------ ---------------------------------------------------- --------------------- ----------
  GO.0009605   Response to external stimulus                        38                    3.22E-12
  GO.0002376   Immune system process                                34                    1.27E-08
  GO.0006955   Immune response                                      26                    3.71E-07
  GO.0009991   Response to extracellular stimulus                   16                    8.57E-07
  GO.0009628   Response to abiotic stimulus                         23                    1.42E-06
  GO.0060548   Negative regulation of cell death                    21                    1.42E-06
  GO.0031667   Response to nutrient levels                          15                    1.79E-06
  GO.0006950   Response to stress                                   40                    2.12E-06
  GO.0051716   Cellular response to stimulus                        54                    2.41E-06
  GO.0007173   Epidermal growth factor receptor signaling pathway   11                    5.14E-06
  GO.0010941   Regulation of cell death                             25                    5.37E-06
  GO.0043066   Negative regulation of apoptotic process             19                    6.83E-06
  GO.0000422   Mitophagy                                            6                     1.42E-05
  GO.0001934   Positive regulation of protein phosphorylation       18                    1.42E-05
  GO.0008284   Positive regulation of cell proliferation            18                    1.42E-05
  GO.0033554   Cellular response to stress                          25                    2.09E-05
  GO.0042981   Regulation of apoptotic process                      23                    2.09E-05
  GO.0044710   Single-organism metabolic process                    42                    2.09E-05
  GO.0050896   Response to stimulus                                 56                    2.38E-05
  GO.0016236   Macroautophagy                                       7                     3.06E-05
  GO.0043410   Positive regulation of MAPK cascade                  13                    3.62E-05
  GO.0016049   Cell growth                                          8                     3.78E-05
  GO.0044712   Single-organism catabolic process                    18                    3.78E-05
  GO.0031668   Cellular response to extracellular stimulus          10                    4.04E-05
  GO.0030334   Regulation of cell migration                         15                    4.43E-05
  GO.0044804   Nucleophagy                                          5                     4.43E-05

**Abbreviations:** FDR, false discovery rate; GO, Gene Ontology; MAPK, mitogen-activated protein kinase.

###### 

Signaling pathway analysis of the genetic interaction network associated with carfilzomib resistance in KMS-11 cell line in terms of GO

  Pathway ID   Signaling pathway                            Observed gene count   FDR
  ------------ -------------------------------------------- --------------------- ----------
  4060         Cytokine--cytokine receptor interaction      13                    1.28E-07
  4140         Regulation of autophagy                      6                     4.82E-06
  280          Valine, leucine and isoleucine degradation   6                     6.81E-06
  1212         Fatty acid metabolism                        6                     8.74E-06
  5215         Prostate cancer                              7                     1.12E-05
  5214         Glioma                                       6                     2.51E-05
  71           Fatty acid degradation                       5                     8.59E-05
  900          Terpenoid backbone biosynthesis              4                     0.000108
  72           Synthesis and degradation of ketone bodies   3                     0.000297
  270          Cysteine and methionine metabolism           4                     0.000733
  5200         Pathways in cancer                           9                     0.000733
  1100         Metabolic pathways                           17                    0.00106
  4962         Vasopressin-regulated water reabsorption     4                     0.00139
  5206         MicroRNAs in cancer                          6                     0.0015
  5212         Pancreatic cancer                            4                     0.00433
  650          Butanoate metabolism                         3                     0.00487
  5218         Melanoma                                     4                     0.00615
  4012         ErbB signaling pathway                       4                     0.0111
  4540         Gap junction                                 4                     0.0111

**Abbreviations:** FDR, false discovery rate; GO, Gene Ontology.
